59019-85-1

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-5-METHOXYBENZOTHIAZOLE is used as a building block for the synthesis of various pharmaceutical compounds, including:
1. Antitumor Agents: It is utilized in the preparation of 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids, which exhibit antitumor properties and are being investigated for their potential in cancer treatment.
2. Glucokinase Activators: 2-AMINO-5-METHOXYBENZOTHIAZOLE is also used in the synthesis of heteroarylcarbamoylbenzene derivatives, which act as glucokinase activators. These activators are relevant for the treatment of diabetes, as they help regulate blood sugar levels by stimulating the enzyme glucokinase.
3. Anti-HBV Agents: Furthermore, 2-AMINO-5-METHOXYBENZOTHIAZOLE is employed in the preparation of dihydropyrimidine compounds, which have demonstrated potential as anti-hepatitis B virus (HBV) agents, offering a therapeutic approach to combat HBV infections.
4. Cannabinoid Receptor Ligands: Additionally, it serves as an intermediate in the synthesis of iminothiazole derivatives, which are known to act as ligands for cannabinoid receptors. These ligands have potential applications in the development of drugs targeting the endocannabinoid system, which is involved in various physiological processes and conditions, such as pain, inflammation, and mood regulation.

Upstream product

• 67-56-1 methanol 
• 3034-22-8 5-bromo-2-aminothiazole 
• 124-41-4 sodium methylate 
• 61296-22-8 5-bromothiazol-2-amine hydrobromide 
• 41663-73-4 2-amino-5-chlorothiazole 

Downstream Products

• 1328983-38-5 2-(4-Cyclopropanesulfonyl-phenyl)-2-(2,4-difluoro-phenoxy)-N-(5-methoxy-thiazol-2-yl)-acetamide 

Relevant academic research and scientific papers

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

Hydantoin and thiohydantoin derivatives as antiviral drugs

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L2, are defined in th

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.